Ionis Pharmaceuticals Inc [NASDAQ: IONS] closed the trading session at $37.81.
The stocks have a year to date performance of -25.26 percent and weekly performance of -8.00 percent. The stock has been moved at -11.72 percent over the last six months. The stock has performed -20.65 percent around the most recent 30 days and changed -17.96 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 1.55M shares, IONS reached to a volume of 2300974 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Ionis Pharmaceuticals Inc [IONS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IONS shares is $61.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IONS stock is a recommendation set at 1.74. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Ionis Pharmaceuticals Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on August 02, 2024. While these analysts kept the previous recommendation, Leerink Partners raised their target price from $53 to $62. The new note on the price target was released on July 24, 2024, representing the official price target for Ionis Pharmaceuticals Inc stock. Previously, the target price had yet another raise from $29 to $75, while Jefferies kept a Buy rating on IONS stock.
The Average True Range (ATR) for Ionis Pharmaceuticals Inc is set at 1.43, with the Price to Sales ratio for IONS stock in the period of the last 12 months amounting to 7.33. The Price to Book ratio for the last quarter was 20.94, with the Price to Cash per share for the same quarter was set at 13.18.
IONS stock trade performance evaluation
Ionis Pharmaceuticals Inc [IONS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.00. With this latest performance, IONS shares dropped by -20.65% in over the last four-week period, additionally sinking by -11.72% over the last 6 months – not to mention a drop of -12.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IONS stock in for the last two-week period is set at 28.35, with the RSI for the last a single of trading hit 22.61, and the three-weeks RSI is set at 32.74 for Ionis Pharmaceuticals Inc [IONS]. The present Moving Average for the last 50 days of trading for this stock 45.61, while it was recorded at 39.43 for the last single week of trading, and 45.19 for the last 200 days.
Ionis Pharmaceuticals Inc [IONS]: An insightful look at the core fundamentals
Ionis Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.51 and a Current Ratio set at 7.61.
Earnings per share (EPS) analysis for Ionis Pharmaceuticals Inc [IONS] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IONS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ionis Pharmaceuticals Inc go to 35.30%.
Ionis Pharmaceuticals Inc [IONS]: Institutional Ownership
There are presently around $95.64%, or 96.39%% of IONS stock, in the hands of institutional investors. The top three institutional holders of IONS stocks are: FMR LLC with ownership of 21.89 million shares, which is approximately 15.044%. VANGUARD GROUP INC, holding 13.85 million shares of the stock with an approximate value of $$659.89 million in IONS stocks shares; and VANGUARD GROUP INC, currently with $$602.41 million in IONS stock with ownership which is approximately 8.6848%.
